Victory Capital Management’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.04M Buy
47,360
+37,087
+361% +$825K ﹤0.01% 1831
2025
Q4
$221K Buy
+10,273
New +$180K ﹤0.01% 2180
2024
Q4
Sell
-730,785
Closed -$10.7M 2504
2024
Q3
$10.7M Buy
730,785
+237,497
+48% +$3.37M 0.01% 1087
2024
Q2
$5.97M Buy
493,288
+138,526
+39% +$2.17M 0.01% 1216
2024
Q1
$8.76M Buy
+354,762
New +$7.2M 0.01% 1100

Other funds holding IMNM

Victory Capital Management's IMNM Position: Q1 2026 in Review

Victory Capital Management increased its Immunome (IMNM) stake by 361% in Q1 2026, buying an estimated $825K and bringing the position to 47,360 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1831.

Victory Capital Management first reported a position in IMNM in Q1 2024 and has held it in 5 quarters since. The position peaked at $10.7M in Q3 2024. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Victory Capital Management held 47,360 shares of Immunome worth $1.04M as of Q1 2026.
  • Victory Capital Management bought 37,087 Immunome shares in Q1 2026, an estimated $825K.
  • Immunome made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1831 holding.
  • Victory Capital Management first reported a position in Immunome in Q1 2024 and has held it in 5 quarters since.
  • Victory Capital Management's Immunome position peaked at $10.7M in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.